Special Issue "Discovery of Enzyme Inhibitors from Natural Products"
Deadline for manuscript submissions: 31 December 2021.
Interests: natural products; drug discovery; enzyme inhibitors; antithrombosis; pharmaceutical analysis
Interests: metabolic syndrome; alcoholic liver disease; nonalcoholic liver disease; atherosclerosis; metabolomics; LC-MS
Enzymes have high catalytic activity, substrate specificity and good biodegradability, which can selectively catalyze a series of biochemical reactions. Inhibition of enzyme activity is considered as a promising approach for treating human diseases. For example, thrombin plays an important role in the processes of thrombosis, and its inhibitors can be used for the treatment of cardiovascular diseases. Glycosidase inhibitors have the potential to be used as drugs for the treatment of diabetes, viral infections, cancers and hereditary lysosomal storage diseases. The inhibition of excessive trypsin activity can be considered as a treatment method for diseases, such as severe acute pancreatitis, fibrosis, hypertension, rheumatoid arthritis and diabetes. Reducing the conversion of xanthine to uric acid by inhibiting the xanthine oxidase activity has become the main approach for the treatment of gout. Tyrosinase inhibitors are potential medicines for the prevention of melanoma and skin tumors.
Natural products are rich sources of new drug discovery, due to their structural diversity. We would like to invite authors to contribute original research and review articles that will stimulate the basic research on the discovery of enzyme inhibitors from natural products. In this Special Issue, we will pay special attention to the manuscripts that evaluate and discuss the screening methods, action mechanisms or expert consensus of natural product-derived enzyme inhibitors. Potential topics suitable for this Special Issue include, but are not limited to:
- Recent advances of discovery of enzyme inhibitors from natural products;
- The use of natural products in the treatment of diseases based on enzyme targets;
- The state-of-the-art technology to discover enzyme inhibitors from natural products;
- SAR studies (structure/activity relationship) of enzyme-targeted natural compounds;
- Natural substances as lead compounds for new drugs in enzyme targeting therapy.
Prof. Dr. Fengqing Yang
Prof. Dr. Jianbo Wan
Dr. Liya Ge
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- enzyme inhibitor
- natural product
- drug discovery